At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
PTG-300drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label Study of PTG-300 in Subjects With Hereditary Hemochromatosis
In Brief
A Phase 2 clinical trial evaluating PTG-300 for Hereditary Hemochromatosis. Completed, enrolled 16 participants across 11 sites in 2 countries.
Detailed Summary
This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Hemochromatosis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartMar 2020
Primary CompletionOct 2021
Study CompletionFeb 2022
TodayJul 2026
First PostedDec 18, 2019
Enrollment StartMar 19, 2020
Primary CompletionOct 6, 2021
Study CompletionFeb 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.5 years ago
Interventions
PTG-300drug
Active treatment with PTG-300 injected subcutaneously.